Recruiting

HIIT

Sponsor:

St. Jude Children's Research Hospital

Code:

NCT07222345

Conditions

Hodgkin Lymphoma

Eligibility Criteria

Sex: All

Age: 10 - 25

Healthy Volunteers: Not accepted

Interventions

High Intensity Interval Training (HIIT)

Study Details

Brief summary:

This pilot study evaluates the feasibility of a 12-week high intensity interval training (HIIT) program in survivors of childhood, adolescent, and young adult Hodgkin lymphoma within 24 months of completing treatment. Preliminary efficacy of the HIIT intervention for improved cardiorespiratory fitness, body composition, physical function, autonomic response to exercise, peripheral neuropathy, biological aging markers, and physical activity will also be evaluated.

Primary Objective:

To determine the feasibility of a 12-week high intensity interval training (HIIT) program in survivors of childhood, adolescent, and young adult Hodgkin lymphoma within 24 months of completing treatment.

Feasibility will be assessed by:

  • Participation Rate: Number of eligible survivors approached who enroll.
  • Completion Rate: Number of scheduled HIIT sessions attended and number of enrolled participants who complete post-intervention testing.

Conditions

Hodgkin Lymphoma

Study ID

NCT07222345

Start date

Jun 8, 2026

Status verified date

Jun, 2026

Completion date

Jan, 2029

Anticipated

Primary completion date

Jan, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 10 - 25

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Participant has been diagnosed with Hodgkin lymphoma between the ages of 10 to 25 years.
  • Participant is between the ages of >10 and <25 years old the time of enrollment.
  • Participant has completed treatment (end of chemotherapy for those not receiving radiation therapy or end of radiation therapy) for Hodgkin lymphoma within 24 months prior to enrollment and recovered from any acute treatment-related adverse events.
  • Participant has been medically cleared to participate in physical activity.
  • Participant verbalizes understanding of directions for use of the web-based platform on the study provided iPad and heart rate monitor.

Exclusion Criteria:

  • Participant has evidence of relapsed disease.
  • Participant has a diagnosis of acute heart failure.
  • Participant reports currently participating in HIIT training or >420 minutes per week of moderate to vigorous physical activity.
  • Female participant who is currently pregnant.

Study Design

Enrollment

20 participants

Anticipated

Intervention Model

Single group

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

experimental: HIIT Intervention Group

Participants will complete a 12-week HIIT program with three 25-minute sessions per week. Each session includes warm-up, five cycles of high-intensity intervals (80-95% peak HR) and recovery periods (50-60% peak HR), and cool-down.

Interventions

High Intensity Interval Training (HIIT)

Participants will complete a 12-week HIIT program with three 25-minute sessions per week. Each session includes warm-up, five cycles of high-intensity intervals (80-95% peak HR) and recovery periods (50-60% peak HR), and cool-down.

Primary outcome measure

  • Participation rate (percent of eligible participants approached who enroll) [ Time Frame: Trial completion (12 weeks) ]
  • Completion rate (percentage of scheduled HIIT sessions attended and percentage of post-intervention testing sessions completed) [ Time Frame: Trial completion (12 weeks) ]

Central Contacts and Locations

Central contacts

Amy Berkman, MD

888-226-4343referralinfo@stjude.org

Locations

St. Jude Children's Research Hospital

Recruiting

Memphis, Tennessee, United States, 38105

Contacts

Amy Berkman, MD

888-226-4343referralinfo@stjude.org

More Information

Sponsor

St. Jude Children's Research Hospital

Last update posted

Jun 10, 2026

Last verified

Jun, 2026

Keywords

  • Childhood Cancer Survivor

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by St. Jude Children's Research Hospital on 2026-06-10.